KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EPS (Basic): 2009-2025

Historic EPS (Basic) for Teva Pharmaceutical Industries (TEVA) over the last 10 years, with Sep 2025 value amounting to $0.38.

  • Teva Pharmaceutical Industries' EPS (Basic) rose 197.44% to $0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.63, marking a year-over-year increase of 174.12%. This contributed to the annual value of -$1.45 for FY2024, which is 190.00% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported EPS (Basic) of $0.38 as of Q3 2025, which was up 52.00% from $0.25 recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' EPS (Basic) ranged from a high of $0.41 in Q4 2023 and a low of -$1.17 during Q4 2022.
  • Its 3-year average for EPS (Basic) is -$0.10, with a median of -$0.12 in 2024.
  • Its EPS (Basic) has fluctuated over the past 5 years, first crashed by 1,328.57% in 2022, then soared by 258.33% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' EPS (Basic) (Quarterly) stood at -$0.14 in 2021, then slumped by 735.71% to -$1.17 in 2022, then surged by 135.04% to $0.41 in 2023, then slumped by 146.34% to -$0.19 in 2024, then soared by 197.44% to $0.38 in 2025.
  • Its EPS (Basic) stands at $0.38 for Q3 2025, versus $0.25 for Q2 2025 and $0.19 for Q1 2025.